Company news
Dimerix Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Final Director's Interest Notice - MD
November 5, 2026
Dimerix Quarterly Activities Report and Appendix 4C
October 28, 2026
Dimerix Quarterly Activities Report and Appendix 4C
October 28, 2026
New Data Supports Biological Rationale for DMX-200 in FSGS
October 22, 2026
2026 AGM Notice of Meeting, Letter of Access and Proxy Form
October 21, 2026
Dimerix Announces Board Chair Transition
October 18, 2026
DMX-200 First 100 Patients Complete Phase 3 Trial Treatment
October 15, 2026
Dimerix at Canaccord Drug & Device and Ignite Conferences
October 11, 2026
First Patient Reaches Four Years in DMX-200 Clinical Program
October 4, 2026
Notification regarding unquoted securities - DXB
September 28, 2026
Notification of 2026 Annual General Meeting Date
September 25, 2026
Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility
September 22, 2026
Dimerix Presents at ASX SMIDcaps Conference 2026
September 22, 2026
Waiver of Listing Rule 10.1 Granted
September 22, 2026
Dimerix Presents at E&P Healthcare Conference 2026
September 15, 2026
Dimerix DMX-652 Granted Mexican Composition of Matter Patent
September 13, 2026
Dimerix Investor Presentation
September 6, 2026
S&P DJI Announces September 2026 Quarterly Rebalance
September 4, 2026
Dimerix secures a$34 million non-dilutive facility to fund key clinical milestones
September 3, 2026
Dimerix Secures A$34 Million Non-Dilutive Funding Facility
September 3, 2026
Trading Halt
September 1, 2026
Appendix 4E and 2026 Annual Report
August 26, 2026
Appendix 4G and Corporate Governance Statement
August 26, 2026
Dimerix Receives US$10M Upfront Payment from Everest
August 19, 2026
Dimerix Assumes Sponsorship of US IND for New Asset DMX-652
August 16, 2026
Dimerix Presents at Bioshares Summit 2026
August 5, 2026
Dimerix Quarterly Activities Report and Appendix 4C
July 29, 2026
US Patent Granted for Dimerix New Asset DMX-652
July 22, 2026
Dimerix expands pipeline with acquisition of Phase 2 ready asset for acute kidney injury
July 17, 2026
Dimerix Expands Pipeline with Acquisition of Phase 2 Asset
July 16, 2026
Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway
July 16, 2026
DMX-200 Available To Patients Via Post-Trial Access Pathways
July 8, 2026
Dimerix exclusively licenses DMX-200 in Greater China, South Korea and Southeast Asia to Everest Medicines
June 15, 2026
Dimerix Licenses DMX200 to Everest for China and Asia Region
June 15, 2026
Dimerix Quarterly Activities Report and Appendix 4C
April 29, 2026
Blinded assessment of ACTION3 statistical assumptions complete
April 27, 2026
ACTION3 Statistical Review Complete
April 27, 2026
Dimerix to Conduct Review of ACTION3 Statistical Assumptions
March 15, 2026
Dimerix Phase 3 Trial Last Patient Receives First Dose
March 9, 2026
Appendix 4D and Half Year Financial Report
February 25, 2026
Quarterly Appendix 4C and Activities Report
January 28, 2026
BioMarin to acquire Dimerix US Partner, Amicus Therapeutics
December 21, 2025
DMX-200 ACTION3 Phase 3 trial completes recruitment
December 15, 2025
DMX-200 ACTION3 Phase 3 Trial Completes Recruitment
December 14, 2025
Successful Completion of Planned IDMC Review
November 18, 2025
Successful PARASOL Collaboration Data Analysis Outcome
October 7, 2025
DMX-200 receives Orphan Drug Designation in Japan
September 29, 2025
Appendix 4E and 2025 Annual Report
August 27, 2025
Dimerix receives 1st Development Milestone payment from FUSO
June 29, 2025
ACTION3 Clinical Trial Milestone Recruitment Update
June 12, 2025
Decks
The 5 newest of 86 decks. Every deck is listed under its year.
- Technical Presentation (October 2026)
Technical · 17 slides · Oct 23, 2026
- Canaccord Genuity Drug and Device Conference 2026
Conference · 35 slides · Oct 12, 2026
- ASX SMIDcaps Conference 2026
Conference · 16 slides · Sep 23, 2026
- E&P Healthcare Conference 2026
Conference · 22 slides · Sep 16, 2026
- Investor Presentation (September 2026)
Investor deck · 35 slides · Sep 7, 2026